Tag Archives: Iptacopan

Novartis 2023 Investor Day Pipeline Updates; New Lilly Obesity Asset

Two cardiometabolic-related news items have been observed: Novartis hosted its 2023 R&D day (press release; webcast; slides); and Lilly initiated a Ph1 SAD/MAD study evaluating a new asset with an unknown MOA (LY3971297) in healthy participants with obesity and hypertension (view CT.gov record). Below, FENIX provides highlights and insights into the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here

Novartis Hosts 2021 R&D Webinar

Novartis hosted its 2021 R&D webinar (view here; slides) and provided a company-wide outlook through 2030 with regard to its cardio-renal pipeline, management focused on Leqvio (PCSK9i for ASCVD), pelacarsen (Lp(a) for ASCVD), and iptacopan (Factor B Complement for nephrology and hematology). There was only brief commentary regarding Entresto’s continued growth. Below, FENIX provides highlights and insights from the Novartis R&D event.

This content is for Read Less members only.
Register
Already a member? Log in here